HELMHOLTZ ZENTRUM MÜNCHEN - DEUTSCHES FORSCHUNGSZENTRUM FÜR GESUNDHEIT UND UMWELT (GMBH) (Germany)
UNIVERSITY OF COPENHAGEN (Denmark)
Inventor
Tiemann, Ulf
Tian, Chenglei
Semb, Henrik
Abstract
The invention relates to a method of differentiating pancreatic bi-potent progenitor cells into beta cells comprising cultivating pancreatic endocrine precursor cells in a medium that promotes the cAMP signalling pathway that lies downstream of apical-basal polarity in endocrine precursors, which can be used to increase the differentiation of progenitor cells into beta cells. Furthermore, the present invention relates to a method of enriching and/or isolating one or more cells expressing a marker of apical-basal polarity, thereby isolating beta cells, and to a method of producing a population of beta cells from a population of human embryonic stem cells. Furthermore, the present invention relates to a population of beta cells obtainable by the method, a pharmaceutical composition comprising the beta cells, a cell culture of progenitor cells in a medium comprising a cAMP agonist, a complex comprising a beta cell bound by the binding agents specific for CD133 and CD49a, and a use of specific binding partners for isolating beta cells.
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
3.
LEGUMES OR PARTS THEREOF WITH REDUCED QUINOLIZIDINE ALKALOID CONTENT
The present invention relates to legumes, preferably non-GMO plants, or parts thereof with decreased or low amounts of quinolizidine alkaloids (QAs) in the seeds. In particular, the invention relates to lupin plants having reduced QA transporter activity, methods for obtaining such and for preparing plant products therefrom.
THE RESEARCH FOUNDATION OF THE CITY UNIVERSITY OF NEW YORK (USA)
UNIVERSITY OF COPENHAGEN (Denmark)
Inventor
Flood, Amar Hugh
Yadav, Ravindra Kumar
Satapathy, Sitakanta
Deshmukh, Prathmesh
Menon, Vinod
Laursen, Bo
Abstract
Disclosed herein is a microcavity and patterns thereof comprising a photoluminescent material positioned between two reflectors, wherein the photoluminescent material comprises a cationic molecular dye, a macrocyclic anion receptor host, and an anion embedded within the macrocyclic anion receptor host and methods of making and using the same.
The present invention relates to the field of plant diterpenoid synthesis, and in particular host cells, methods and uses therefor. More specifically, the invention relates to production of taxol and/or other taxanes having a side chain comprising an N- benzoylated or an N-acetylated β-phenylalanine moiety, as well as enzymes and host cells useful for such production.
The present invention provides bioorthogonal tetrazine reaction entities for use in pretargeting approaches comprising imaging, therapy and diagnostics specifically pretargeting theranostics. The present invention also provides precursors of the tetrazine reaction entities and kits comprising the tetrazine reaction entity or the precursor of the tetrazine reaction entity and a dienophile with inverse electron demand Diels-Alder cycloaddition reactivity.
Escherichia coliEscherichia coli (APEC) strain and a method for obtaining outer membrane vesicles (OMV) therefrom. The OMVs may be obtained in high concentrations suitable for use in aerosol vaccine preparations.
The invention provides a method for obtaining one or more supporting bacteria for a bacterial composition. The invention further provides devices and kits, which may be used in such methods, and uses of such devices and kits. Such supporting bacteria may be suitable for formation of synthetic bacterial consortia.
The invention provides a method for co-isolating two or more bacterial strains co-located on a micro-scale surface. Such co-isolated bacteria may be suitable for formation of synergistic bacterial consortia.
C12Q 1/04 - Determining presence or kind of microorganismUse of selective media for testing antibiotics or bacteriocidesCompositions containing a chemical indicator therefor
C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
11.
Stencil mask and use thereof in lithography fabrication
The disclosure relates to a stencil mask, a method for manufacturing the stencil mask and use of the stencil mask in nanoscale device nanofabrication, including imprinting on substrates of deposition patterns for nanoscale devices. One embodiment relates to a stencil mask for manufacturing at least one nanoscale device on a substrate, the stencil mask comprising, a membrane having a top surface and bottom surface and a thickness therebetween of at least 500 nm, a predefined pattern of apertures extending through the membrane, each aperture having a width and a length in the top surface of the membrane, wherein at least the width and/or the length of one of said apertures is of less than 100 nm, each aperture defined by inner sidewalls extending between the top surface and the bottom surface of the membrane, and a set of separating nanostructures on the top surface of the membrane for separating the top surface of the membrane from a top surface of the substrate.
The present invention provides a method for treating spasticity in a subject. The method includes direct administration of a herpes simplex virus 1 (HSV-1) vector harboring a glutamic acid decarboxylase (GAD) gene (preferably. GAD67) into one or more dermatomes of the subject.
The present disclosure relates to compositions and methods for treating and/or preventing malarial infections. In some embodiments, the present disclosure provides recombinant antibodies and compositions thereof for treating and/or preventing a malarial infection. The present disclosure also provides methods of using the recombinant antibodies and compositions thereof to treat and/or prevent a malarial infection.
in vitroin vivoin vivo in a subject as well as methods for detecting or evaluating a level of oxygen in a target. A method of identifying an agent capable of modulating partial oxygen tension in a tissue of a subject and a method of evaluating an effect of an agent on partial oxygen tension in a tissue of a subject are also disclosed. The methods involve introducing or expressing in the tissue or in one or more cells therein a luminescent protein capable of oxidizing a substrate with oxygen in the tissue, wherein oxidization of the substrate by the luminescent protein results in emission of a bioluminescence signal, and wherein intensity of the bioluminescence signal is correlated to a level of oxygen in the tissue; contacting the tissue with the substrate under a condition permitting oxidization of the substrate by the luminescent protein and emission of the bioluminescence signal; and imaging or evaluating the partial oxygen tension in the tissue by detecting the bioluminescence signal or determining a level of the bioluminescence signal. Preferably the luminescent protein is a fusion protein comprising a luciferase fused to a fluorescent protein.
C12Q 1/66 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving luciferase
The present invention relates to humanized antibodies and molecular conjugates targeting Urokinase type plasminogen activator receptor associated protein (uPARAP), in particular antibody-drug conjugates (ADCs) comprising humanized antibodies directed against uPARAP and their use in delivery of active agents to cells and tissues expressing uPARAP. The invention further relates to the use of said ADCs in the treatment of diseases involving uPARAP expressing cells, such as certain cancers.
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
A61K 51/10 - Antibodies or immunoglobulinsFragments thereof
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
in vitroin vitro fertilization (IVF) media. The present invention further relates to the use of a membrane-permeable form of alpha-ketoglutarate to improve human embryo trophectoderm quality, and to the use of a medium supplemented with a cell membrane-permeable form of alpha- ketoglutarate to improve embryo trophectoderm quality, preferably human embryo trophectoderm quality. The present invention also provides methods for obtaining embryos with improved trophectoderm quality, comprising culturing said embryos in a medium supplemented with a membrane-permeable form of alpha-ketoglutarate.
Described herein are methods for differentiating pluripotent stem cells, such as human embryonic stem cells, to arcuate nucleus progenitor cells, and mature arcuate nucleus neurons and tanycytes. The methods comprise a cell patterning and expansion phase comprising culturing the cells in the presence of BMP4 and/or BMP7 and IGFBP3, and/or a cell maturation phase comprising culturing the cells in the presence of BMP7. Also described are cells obtained by the methods, and arcuate nucleus progenitor cells populations expressing RAX, TBX3 and NKX2-1 according to the present invention. Kits comprising elements for performing the methods of the present invention, and/or10 comprising cells of the according to the present invention are also described.
The present invention provides in-vitro cell populations of arcuate nucleus cell types, such as tuberal progenitor cells, neurons and/or tanycytes, characterized by the expression of cell surface markers. The present invention also provides methods for 5 identifying populations of arcuate nucleus cell types expressing said markers. The invention also discloses positive and negative sorting selection steps based on expression of said markers. The present invention finally provides kits for performing the methods described herein.
The present invention concerns a method for site-selective modification of a target protein or peptide by use of an acylation tag comprising a single lysine residue and at least three histidine residues. Upon contact with an acylating reagent, the target protein or peptide becomes modified at the ε-amine of the lysine residue of the acylation tag.
The present disclosure relates to peptides and peptide analogues with high affinity for the PDZ domains of PICK1. The peptide or peptide analogue interacts with PICK1, blocking the native protein-protein interactions between PICK1 and its natural ligands. The disclosure furthermore relates to the therapeutic use of these peptides and peptide analogues in prevention and/or treatment of diseases and disorders associated with maladaptive plasticity, drug addiction and neuropathic pain.
The invention regards a stencil mask for defining a pattern on a substrate during evaporation of material from an evaporation source, the stencil mask comprising, a membrane having a top surface and bottom surface defining a first thickness of the membrane, at least one barrier projecting from the bottom surface of the membrane, each barrier defining a second thickness of the membrane between the top surface of the membrane and a lower surface of the barrier, such that the second thickness of the membrane is larger than the first thickness of the membrane for each barrier, and at least one slit extending from the top surface of the membrane to a lower surface of a barrier, such that the barrier forms a downwardly projecting edge of the slit, wherein an aspect ratio between the first thickness of the membrane or the second thickness of the membrane, and the width of the slit, is at least 2.
The present disclosure regards a method for providing labeled single isomeric chemical entity targeting vectors suitable for providing targeting vectors. The method applies specific combinations between a diene and a dienophile with complementary inverse electron demand Diels-Alder cycloaddition reactivity, which upon ligation, followed by oxidation, will form compounds of a single isomeric form. The labeled single isomeric chemical entity targeting vectors are for use in therapy, radiotherapy, theranostics, diagnostics, and imaging. The method applies click chemistry wherein one chemical entity which is conjugated to a label is clicked together with a second chemical entity with complementary inverse electron demand Diels-Alder cycloaddition reactivity which is conjugated to a targeting vector followed by a rapid oxidation, to form a single isomeric compound.
The present invention relates to the field of plant diterpenoid synthesis, and in particular host cells, methods and uses therefor. More specifically, the invention relates to production of a taxane having a side chain comprising a hydroxylated β- phenylalanine moiety, as well as enzymes and host cells useful for such production.
A61K 31/337 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
C07D 305/14 - Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms condensed with carbocyclic rings or ring systems
C12N 15/82 - Vectors or expression systems specially adapted for eukaryotic hosts for plant cells
The present invention relates to a method for predicting the risk of post-operative recurrence of a cancer, and applications thereof in: methods for predicting survival of said subject; methods of prognosis of said subject; methods to administer adjuvant chemotherapy to said subject; and methods to prevent or decrease the risk of recurrence of the cancer in said subject. The methods involve quantifying the level of adhesion of a cell population cultured in the presence of a blood sample from the subject prior to and after surgical resection of the cancer.
The present disclosure relates to mutant human NaX ion channel (“NaX”) proteins and screening methods using a mutant human NaX that may be used to identify molecules that modulate the activity of human NaX. For example, in some embodiments, screening methods involve performing an ion channel assay on a mutant human NaX in the presence of a potential NaX modulator. The disclosure also relates to molecules that act as modulators of human NaX and associated kits for detecting such molecules.
G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
The present invention relates to mutant Cpf1 endonucleases having altered activity compared to the wild type Cpf1, and their use to introduce single strand breaks in nucleic acid sequences. Methods for detection and quantification of a nucleic acid sequence are also disclosed. Methods for diagnosis of an infectious disease are also disclosed.
According to the invention there is provided methods for making heparan sulfate with increased anticoagulant activity wherein the resulting product has a lower heterogeneity and presents an improved safety profile compared to conventional animal-sourced heparin.
The present invention relates to antibodies and molecular conjugates targeting the receptor uPAR, in particular antibody-drug conjugates (ADCs) of said antibodies and their use in delivery of active agents to cells and tissues expressing uPAR. The invention further relates to the use of said ADCs in the treatment of diseases involving uPAR expressing cells, such as certain cancers.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
29.
IMPROVED TYPE V-K CRISPR-ASSOCIATED TRANSPOSON MUTANTS
The present disclosure provides protein components of Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-associated transposon complex systems with increased transposition efficiency and/or modified recognition/insertion site distance.
The present invention relates to donor DNA molecules that provide an increased transposition efficiency when used with Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-associated transposon complex systems, such as Type V-K CRISPR-associated transposon complex systems.
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 38/47 - Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
A61K 31/167 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen atom of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
A61K 31/704 - Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin, digitoxin
A61K 31/7048 - Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin
A61K 38/50 - Hydrolases (3) acting on carbon-nitrogen bonds, other than peptide bonds (3.5), e.g. asparaginase
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
The present invention relates to the field of biosynthesis of compounds of cytochrome P450 (CYP450) pathways. More specifically the invention relates to host cells and methods for improving production of compounds of CYP450 pathways, for example methods and cells for improving titers and/or purity.
C12N 15/00 - Mutation or genetic engineeringDNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purificationUse of hosts therefor
An assembly comprising a qubit and a method of altering a qubit, where a presence of a charge in a storage element close to the qubit influences on the state in which the altering is performed. Then, altering may be performed by feeding signals to electrodes, where the same signal is fed to the qubit but where the state is altered only if the charge is present in the storage element. Multiple qubits may then receive the same signal and only the ones with a charge are altered by the signal.
The present invention relates to a medium, also referred to as enhanced metabolic medium, for culturing mammalian pluripotent stem cells and methods of using the same to maintain pluripotency.
NORTHERN CARE ALLIANCE NHS FOUNDATION TRUST (United Kingdom)
Inventor
Lock Rud, Charlotte
Lodberg Hvas, Christian
Ramer Mikkelsen, Ulla
Jensen, Erik
Schouw Andersen, Peter
Bekker Jeppesen, Palle
Lal, Simon
Hollyer, Tristan Richard
Abstract
The present invention relates to a composition for use in the treatment of a condition selected from malabsorption in patients with ileostomy, malnutrition in patients with ileostomy, sodium depletion in patients with ileostomy and/or dehydration in patients with ileostomy.
The present disclosure relates to a spin qubit system comprising a quantum dot unit comprising a planar nanophotonic waveguide comprising a grating coupler, and a nano beam waveguide section for guiding photons and a photonic bandgap waveguide section, the quantum dot unit further comprises a quantum dot configured to interact with the planar photonic bandgap waveguide, and an electrode for applying a DC electric field to the quantum dot. The spin qubit system further comprises a quarter wavelength resonator in a coplanar waveguide configuration comprising an open input end having three input electrodes, and a closed resonator end wherein the three input electrodes are shorted at the closed resonator end by a conducting material.
The present invention relates to a method for providing pyridazines by rapid oxidation of dihydropyridazines. The pyridazines can be used in therapy such as radiotherapy, diagnostics, imaging, and other photochemistry methods. The method applies to dihydropyridazine mixture that arises from the click reaction between a first chemical entity which is either a 1,2,4,5-tetrazine or a strained alkene having inverse electron demand Diels-Alder cycloaddition reactivity and a second chemical entity which is either a 1,2,4,5-tetrazine or a strained alkene having complementary inverse electron demand Diels-Alder cycloaddition reactivity. The ligation between the first chemical entity and the second chemical entity is followed by a rapid acid catalyzed oxidation.
C07D 209/94 - [b, c]- or [b, d]-condensed containing carbocyclic rings other than six-membered
C07B 59/00 - Introduction of isotopes of elements into organic compounds
C07D 235/02 - Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
C07D 237/08 - Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
C07D 241/36 - Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
C07D 401/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
The invention concerns a compound of formula (I), a pharmaceutical formulation comprising the compound of formula (I) and use of the pharmaceutical composition for treating fibrotic, inflammatory, diabetic or cognitive disease.
The invention concerns a compound of formula (I), a pharmaceutical formulation comprising the compound of formula (I) and use of the pharmaceutical composition for treating fibrotic, inflammatory, diabetic or cognitive disease.
C07D 405/12 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
A61K 31/4433 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
A61K 31/444 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. amrinone
A61K 31/4709 - Non-condensed quinolines containing further heterocyclic rings
C07D 405/14 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
C07D 413/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
The present disclosure regards a qubit circuit comprising at least first and second data qubits and a mediator qubit coupling the first and second data qubits in a circuit plane, wherein the first data qubit and the second data qubit are coupled to the mediator qubit by means of respective twist couplers, each twist coupler comprising superconducting regions connected by superconducting transmission lines, wherein at least two of the connecting transmission lines cross each other at a line crossing point where the crossing transmission lines are separated by an insulator layer.
The present disclosure regards PSMA targeting urea-based ligands comprising a PSMA targeting moiety, a linker, and a pyridazine moiety. The PSMA targeting urea-based ligands disclosed are suitable for use as radiopharmaceuticals, either as imaging agents, such as diagnostic agents, or for the treatment of prostate cancer or as theranostic agents.
A METHOD FOR DETERMINING A CHARGE-STATE BOUNDARY OF A QUANTUM DOT, A MULTI-DOT DEVICE, OR AN ARRAY OF QUANTUM DOTS AND A DATA PROCESSING SYSTEM FOR PERFORMING THE METHOD
Disclosed is a method for determining a charge-state boundary of a quantum dot, a multi-dot device, or an array of quantum dots, including the steps of defining an initial point inside a charge state of a quantum dot having a charge-state boundary, ramping gate voltages from the initial point thereby creating a plurality of rays in gate voltage space, creating a time stamp when each of the rays leave the charge-state/cross the charge-state boundary, and constructing the boundary of the charge state by correlating each ray in gate voltage space with the associated time stamp.
G01N 27/22 - Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating impedance by investigating capacitance
G06N 10/40 - Physical realisations or architectures of quantum processors or components for manipulating qubits, e.g. qubit coupling or qubit control
46.
NOVEL SELECTION METHODS FOR THE DISCOVERY OF POLYPEPTIDES WITH SPECIFIC ASSEMBLY AND AGGREGATION PROPERTIES
The present invention relates to the field of plant diterpenoid synthesis, and in particular methods and host cells therefor. More specifically, the invention relates to production of taxanes comprising an oxetane, taxanes comprising an oxetane and acetoxy group and taxanes hydroxylated at position 10, 11 and/or 13, as well as enzymes and host cells useful for such production.
The disclosure regards a computer implemented method for determining boundary locations of a phase state in a charge stability diagram of capacitively coupled quantum dots, comprising the steps of applying a first voltage vector in the charge stability diagram generated by the coupled quantum dots for defining a first phase state of the coupled quantum dots, determining a phase transition location of the coupled quantum dots from the first phase state to a neighboring second phase state in the charge stability diagram by varying the voltage vector for changing energy levels of the states of the quantum dots until a phase transition occurs, repeating the aforementioned steps for at least a second voltage vector, and fitting the phase transition locations to a plurality of sets of fitting parameters for determining boundary locations of the phase state, wherein at least one set of the plurality of sets of fitting parameters is a set of non-linear fitting parameters extracted by means of a machine learning model, such as a deep neural network.
A circuit for transferring charge, which may be in the form of charged particles from a first storage element to one of a plurality of second storage elements, the circuit comprising a circuit element configured to receive the charge or charged particles and deliver the charge or charged particles to an identified one of the plurality of second storage elements. The charge delivered may be the same charged particles or other charged particles. The circuit may be used for embodying Boolean circuits or gates operable at cryo temperatures.
The present invention relates to polypeptides derived from Ruminococcus torques, and polypeptide fragments and variants thereof useful for treatment and/or prevention of metabolic disorders, muscle disorders and injuries, and bone disorders, and host cells comprising said polypeptides, polypeptide fragments or variants thereof for use as a probiotic or as a Live Biopharmaceutical Product (LBP).
A sensor for a cryogenic operated device, the set-up comprising dual quantum dots positioned so close to a conductor supplying an electrical signal to the device. A charged particle in the quantum dots is affected and moved due to the field, so that detection of the position of the particle will provide information relating to the field and thus the signal.
The present disclosure relates, inter alia, to complexes of the Na+ leak channel non-selective protein (NALCN) with FAM155A (also called FAM155; Family with sequence similarity 155 member A), UNC79 (uncoordinated 79), and UNC80 (uncoordinated 80), methods of screening for molecules that modulate the activity of the complex, and identified modulators thereof.
G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
G01N 33/557 - ImmunoassayBiospecific binding assayMaterials therefor using kinetic measurement, i.e. time rate of progress of an antigen-antibody interaction
55.
NUCLIDE LABELLED H-TETRAZINES AND USE THEREOF FOR PET AND SPECT PRETARGETED IMAGING AND RADIONUCLIDE THERAPY
The present invention relates to novel tetrazine compounds for use in pretargeted in vivo imaging and in therapy and to the precursors of the tetrazine compounds. The compounds are suitable for use in click chemistry. i.e. reactions that join a targeting molecule and a reporter molecule. The compounds comprise a radionuclide of F, I or At and on or more polar groups providing that the compounds can efficiently react with extracellularly located pretargeting vectors and as such used for example for pretargeted cancer diagnostics and cancer therapy.
A quantum lab chip for quantum experiments is disclosed. The lab chip comprises a plurality of different device regions, each device region comprising quantum electronic devices requiring similar experimental conditions, wherein at least a first device region may comprise at least one semiconductor device, at least a second device region may comprise at least one superconductor on insulator device, and at least a third device region may comprise hybrid semiconductor-superconductor devices.
There are provided compositions and mucin-binding targeting agents derived from microbial proteins that have selective binding properties for densely glycosylated mucins as well as such compositions and targeting agents comprising a binding moiety and/or a pay load which may be attached to the binding moiety or directly to a targeting agent. The compositions and targeting agents may be used as medicaments in the treatment of a disease, illness, or disorders.
A method of treatment or prophylaxis of kidney injury in patient (for example in an infant such as a preterm infant and/or a low gestational weight baby and/or baby born following preeclampsia) by administering a therapeutic amount of a composition comprising IGF-1 and an IGF binding protein (such as IGFBP-3), for example as complex. An alternative method minimises the systemic inflammatory state of an infant. The disclosure also extends to compositions used in the treatment of kidney injury (such as acute kidney injury) and/or systemic inflammation of an infant and the manufacture of a medicament for the same ends.
A61K 38/30 - Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
A61P 25/00 - Drugs for disorders of the nervous system
The present invention relates to designed water for brewing of coffee. Specifically the designed water of the invention can be used to prepare good-tasting coffee.
The present invention relates to compounds capable of binding to the PDZ domains of PSD-95 and their medical use as inhibitors of protein-protein interaction mediated by PSD-95.
A61K 47/64 - Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
62.
LIPID NANODISCS USEFUL IN SOLUBILISING MEMBRANE PROTEINS
Provided herein are composition including lipids and copolymers in the form of a nanodisc assembly. The copolymers include monomer units of methacrylic acid and styrene. Also provided herein is an aqueous solution comprising the subject composition, methods of producing the nanodisc assembly. Further provided are methods of solubilising hydrophobic constituents such as membrane proteins in aqueous solution, including forming nanodisc assemblies of a lipid, the hydrophobic constituent, and the subject copolymer.
The present invention relates to conjugates targeting uPARAP, in particular antibody-drug conjugates (ADCs) comprising monoclonal antibodies directed against the N-terminal region of uPARAP, and their use in delivery of active agents to cells and tissues expressing uPARAP. The invention further relates to the use of said ADCs in the treatment of diseases involving uPARAP expressing cells, such as cancer.
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C07K 16/32 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products from oncogenes
64.
SMALL HYDROPHOBIC PROTEIN DRUG CONJUGATES AND USES THEREOF
The present disclosure provides peptide conjugated drugs based on MuV SH Protein, their use as therapeutic agents and their use to provide delivery to and/or transfer across a membrane of the drug. The present disclosure provides use of the peptide conjugated drug for delivery of the drug to and/or across a membrane harbouring G protein-coupled receptor 125 (GPR125), such as the choroid plexus.
A61K 47/64 - Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
A61K 38/16 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof
The present invention provides a pathway for production of (-)-sparteine. In particular, enzymes involved in the pathway are provided as well as nucleic acids encoding same. The invention also provides host cells capable of producing (-)-sparteine or precursors thereof, as well methods of producing (-)-sparteine or precursors thereof.
The present disclosure relates novel cyclic peptides which can act as inhibitors of protein-protein interactions, specifically by inhibiting the PDZ2 domain of PSD-95, for use in treatment of excitotoxicity-related diseases and neuropathic pain.
THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (USA)
UNIVERSITY OF COPENHAGEN (Denmark)
Inventor
Fordyce, Polly M.
Hein, Jamin B.
Abstract
The disclosure provides methods and compositions for evaluating phosphatase and kinase activity using spectrally encoded microbeads comprising substrate peptides in which there is a 1:1 linkage between sequences of the substrate peptide and the embedded spectral code.
C40B 20/04 - Identifying library members by means of a tag, label, or other readable or detectable entity associated with the library members, e.g. decoding processes
C40B 30/04 - Methods of screening libraries by measuring the ability to specifically bind a target molecule, e.g. antibody-antigen binding, receptor-ligand binding
C40B 40/10 - Libraries containing peptides or polypeptides, or derivatives thereof
A system for determining information relating to a first periodic signal, the system comprising a sequence of storage elements each configured to store at least one charged particle, where a signal with a constant voltage and a signal with a varying voltage is fed to each storage element. One of the signals with the varying voltage is the first periodic signal. By monitoring the current pumped between the storage elements by the voltages applied to the storage elements, the information relating to the first periodic signal may be generated.
THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (USA)
UNIVERSITY OF COPENHAGEN (Denmark)
Inventor
Fordyce, Polly, M.
Hein, Jamin B.
Abstract
The disclosure provides methods and compositions for identifying agents that modulate binding of a protein to a peptide binding partner using spectrally encoded microbeads comprising binding site peptides in which there is a 1:1 linkage between sequences of the binding site peptide and the embedded spectral code.
G01N 33/543 - ImmunoassayBiospecific binding assayMaterials therefor with an insoluble carrier for immobilising immunochemicals
B82Y 5/00 - Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
G01N 33/542 - ImmunoassayBiospecific binding assayMaterials therefor with immune complex formed in liquid phase with steric inhibition or signal modification, e.g. fluorescent quenching
The present disclosure relates to a stencil mask for defining a plurality of patterns on a substrate during evaporation of material from an evaporation source, the stencil mask comprising a membrane having a top surface and bottom surface and a thickness therebetween of at least 200 nm defining the thickness of the membrane, and a at least one set of parallel slits extending through the thickness of the membrane, wherein the slits are defined such that the material coming from an evaporation source is blocked by the mask or deposited onto the substrate depending on the alignment of said source with the stencil mask.
C23C 14/04 - Coating on selected surface areas, e.g. using masks
C23C 14/22 - Coating by vacuum evaporation, by sputtering or by ion implantation of the coating forming material characterised by the process of coating
The present disclosure relates to a method of manufacturing a transferable lamella comprising interconnected nanostructures, the method comprising the steps of: a) providing a substrate such as a planar substrate; b) forming at least one superstructure on the substrate, said superstructure comprising a plurality of elongated nanostructures (formed e.g. by growth, deposition, and/or etching); wherein the elongated nanostructures are formed such that at least two of said nanostructures are conductively interconnected, and/or wherein at least a first layer is grown or deposited to conductively interconnect or insulate at least a part of the elongated nanostructures; c) encapsulating at least a portion of said superstructure in an encapsulating material, said portion comprising at least two interconnected nanostructures; and d) cutting the encapsulating material in a direction that intersects at least two interconnected nanostructures, thereby manufacturing a transferable lamella comprising interconnected nanostructures. The present disclosure further relates to an electronic device manufactured from one or more of the lamellas provided by the method.
C30B 29/60 - Single crystals or homogeneous polycrystalline material with defined structure characterised by the material or by their shape characterised by shape
C30B 11/12 - Vaporous components, e.g. vapour-liquid-solid-growth
C30B 29/66 - Crystals of complex geometrical shape, e.g. tubes, cylinders
H01L 29/06 - Semiconductor bodies characterised by the shapes, relative sizes, or dispositions of the semiconductor regions
H01L 29/20 - Semiconductor bodies characterised by the materials of which they are formed including, apart from doping materials or other impurities, only AIIIBV compounds
H01L 31/0352 - SEMICONDUCTOR DEVICES NOT COVERED BY CLASS - Details thereof characterised by their semiconductor bodies characterised by their shape or by the shapes, relative sizes or disposition of the semiconductor regions
H01L 33/06 - SEMICONDUCTOR DEVICES NOT COVERED BY CLASS - Details thereof characterised by the semiconductor bodies with a quantum effect structure or superlattice, e.g. tunnel junction within the light emitting region, e.g. quantum confinement structure or tunnel barrier
The present invention provides a method for treating spasticity in a subject. The method includes direct administration of a herpes simplex virus 1 (HSV-1) vector harboring a glutamic acid decarboxylase (GAD) gene (preferably, GAD67) into one or more dermatomes of the subject.
Up until now, only low reactivity Tzs can be radiolabeled via direct aliphatic SN2. Unfortunately, these structures display too low reactivity for in vivo bioorthogonal chemistry approaches. Highly reactive structures such as mono-unsubstituted tetrazines (H-Tzs) have been reported to be highly sensitive to base. Extensive degradation is observed which prevents isolation of meaningful amounts for imaging studies.
Up until now, only low reactivity Tzs can be radiolabeled via direct aliphatic SN2. Unfortunately, these structures display too low reactivity for in vivo bioorthogonal chemistry approaches. Highly reactive structures such as mono-unsubstituted tetrazines (H-Tzs) have been reported to be highly sensitive to base. Extensive degradation is observed which prevents isolation of meaningful amounts for imaging studies.
In the present invention there is provided a method providing the possibility to radiolabel base sensitive tetrazine structures with significantly improved RCYs. Even tetrazines that were previously not accessible by applying “standard” aliphatic 18F-labeling strategies can be radiolabeled. This places new classes of 18 F-fluorinated compounds within reach for application in PET imaging studies such as for diagnosis of cancers.
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
The present invention relates to a series of noncovalent Keap1-Nrf2 small-molecule inhibitors and their use as medicaments. The series comprises novel small-molecule analogues with strong affinity for the Keap1 Kelch domain and ability to inhibit the Keap1-Nrf2 interaction.
C07D 307/81 - Radicals substituted by nitrogen atoms not forming part of a nitro radical
C07D 317/60 - Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
C07D 319/18 - Ethylenedioxybenzenes, not substituted on the hetero ring
A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
A61P 37/00 - Drugs for immunological or allergic disorders
C07D 405/06 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
C07D 417/06 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
The present invention provides Brassicales plants, or parts thereof, having a low UMAMIT glucosinolate transporter activity. In particular, Brassicales plants carrying a mutation in a gene encoding an UMAMIT transporter and having a low seed glucosinolate content are provided. Furthermore, plant products prepared from said Brassicales plants, or parts thereof, are described, as well as methods of producing said plants.
The present invention provides Brassicales plants, or parts thereof, having a low UMAMIT glucosinolate transporter activity. In particular, Brassicales plants carrying a mutation in a gene encoding an UMAMIT transporter and having a low seed glucosinolate content are provided. Furthermore, plant products prepared from said Brassicales plants, or parts thereof, are described, as well as methods of producing said plants.
Norges Miljo-Og BIovitenskapelige Universitet (NMBU) (Norway)
Sykehuset Ostfold HF (Norway)
University of Copenhagen (Denmark)
Inventor
Lea, Tor
Kleiveland, Charlotte
Kristiansen, Karsten
Jensen, Benjamin Anderschou Holbech
Holm, Jacob Bak
Larsen, Ida Sogaard
Jacobsen, Morten
Abstract
Described is a method for the treatment or prevention of GI tract dysbiosis in a subject, said method including administering an effective amount of a non-viable Methylococcus capsulatus or a lysate of Methylococcus capsulatus to said subject. The invention further provides a method for the treatment or prevention of a disease or condition selected from small intestine bacterial overgrowth (SIBO), small intestine fungal overgrowth syndrome (SIFO), GI tract cancers, breast cancer, neurological disorders, malnutrition, chronic fatigue syndrome, autism, cardiovascular diseases and GI tract infections in a subject with GI tract dysbiosis, said method including administering an effective amount of a non-viable Methylococcus capsulatus or a lysate of Methylococcus capsulatus to said subject. A non-viable Methylococcus capsulatus or a lysate of Methylococcus capsulatus for use in said methods is further provided.
The present disclosure relates to agonists of Tacr2, such as peptides agonist of Tacr2 and methods of using the same for treatment of insulin resistance, obesity and/or diabetes. The disclosure also relates to use of said agonists of Tacr2 for enhancement of energy consumption in an individual.
A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
The present invention relates to modular nanoparticle-based compositions based on nucleic acids, such as DNA and RNA, which are particularly useful in prophylaxis and/or treatment of diseases and disorders.
The present invention relates to a method of quantifying methane removal in the atmosphere. Specifically, the present invention relates to quantifying methane removal by iron-salt aerosols. The present invention also relates to the method for use for the purpose of claiming a carbon credit.
The present invention relates to isolated polypeptides derived from stanniocalcin-2 (STC2), and polypeptide fragments and variants thereof useful for inhibiting proteolytic activity of the pregnancy-associated plasma protein-A (PAPP-A), as well as methods for identifying ligands and inhibitors of PAPP-A.
A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
The present invention relates to mutated bacterial host cells, said host cells producing a polypeptide of interest and having at least one disrupted flagellum gene, and to nucleic acid constructs and vectors encoding at least one flagellum polypeptide with reduced or eliminated activity as well as to methods of producing one or more polypeptide of interest in said host cells.
THE RESEARCH FOUNDATION OF THE CITY UNIVERSITY OF NEW YORK (USA)
UNIVERSITY OF COPENHAGEN (Denmark)
Inventor
Flood, Amar H.
Yadav, Ravindra Kumar
Satapathy, Sitakanta
Deshmukh, Prathmesh
Menon, Vinod
Laursen, Bo
Abstract
Disclosed herein is a microcavity comprising a photoluminescent material positioned between two reflectors, wherein the photoluminescent material comprises a cationic molecular dye, a macrocyclic anion receptor host, and an anion embedded within the macrocyclic anion receptor host and methods of making and using the same.
C07C 255/49 - Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
C07C 255/58 - Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the carbon skeleton
C07D 209/56 - Ring systems containing three or more rings
H10K 85/60 - Organic compounds having low molecular weight
H10K 50/11 - OLEDs or polymer light-emitting diodes [PLED] characterised by the electroluminescent [EL] layers
87.
A FLEXIBLE FOIL FOR THE DELIVERY OF THERAPEUTIC CARGOS
The present invention relates to a drug delivery platform. In particular, it relates to a foil-based drug delivery platform for delivery to the intestine.
INDUSTRY FOUNDATION OF CHONNAM NATIONAL UNIVERSITY (Republic of Korea)
UNIVERSITY OF COPENHAGEN (Denmark)
Inventor
Na, Kyung Su
Choi, Yu Yeol
Lee, Ji Woong
Milia, Marco
Abstract
22) is inhibited by the chloride ion adsorbent while producing hydrogen without treating seawater to freshwater. In the absence of the chloride ion adsorbent, otherwise, a large amount of chloride ions (Cl-) will be oxidized during electrolysis due to NaCl dissolved in a large amount in seawater.
B01J 20/10 - Solid sorbent compositions or filter aid compositionsSorbents for chromatographyProcesses for preparing, regenerating or reactivating thereof comprising inorganic material comprising silica or silicate
B01J 20/28 - Solid sorbent compositions or filter aid compositionsSorbents for chromatographyProcesses for preparing, regenerating or reactivating thereof characterised by their form or physical properties
B01J 20/30 - Processes for preparing, regenerating or reactivating
C25B 1/04 - Hydrogen or oxygen by electrolysis of water
The present invention relates to co-amorphous form of a substance and a protein. The present invention also relates to pharmaceutical, cosmetic or veterinary compositions comprising the co-amorphous form as well as to methods for preparing and using the co-amorphous form.
A61K 47/34 - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
90.
Lysosomal enzymes modified by cell based glycoengineering
The present invention relates to lysosomal enzymes modified by use of cell based methods, a compositions comprising a modified lysosomal enzyme, as well as methods for producing a modified lysosomal enzyme and therapeutic use of such modified lysosomal enzyme. In particular, the present disclosure relates to a modified lysosomal enzyme which has low Man6P and low exposed Mannose and high sialic acid content of alpha2,3 type enabling long circulation time and improved uptake into difficult-to-reach organs like heart, kidney and brain.
The disclosure relates to a stencil mask, a method for manufacturing the stencil mask and use of the stencil mask in nanoscale device nanofabrication, including imprinting on substrates of deposition patterns for nanoscale devices. One embodiment relates to a stencil mask for manufacturing at least one nanoscale device on a substrate, the stencil mask comprising, a membrane having a top surface and bottom surface and a thickness therebetween of at least 500 nm, a predefined pattern of apertures extending through the membrane, each aperture having a width and a length in the top surface of the membrane, wherein at least the width and/or the length of one of said apertures is of less than 100 nm, each aperture defined by inner sidewalls extending between the top surface and the bottom surface of the membrane, and a set of separating nanostructures on the top surface of the membrane for separating the top surface of the membrane from a top surface of the substrate.
G03F 1/20 - Masks or mask blanks for imaging by charged particle beam [CPB] radiation, e.g. by electron beamPreparation thereof
C23C 14/04 - Coating on selected surface areas, e.g. using masks
C23C 16/04 - Coating on selected surface areas, e.g. using masks
C23C 18/16 - Chemical coating by decomposition of either liquid compounds or solutions of the coating forming compounds, without leaving reaction products of surface material in the coatingContact plating by reduction or substitution, i.e. electroless plating
C25D 5/02 - Electroplating of selected surface areas
92.
STENCIL MASK AND USE THEREOF IN LITHOGRAPHY FABRICATION
C23C 14/04 - Coating on selected surface areas, e.g. using masks
C23C 16/04 - Coating on selected surface areas, e.g. using masks
C23C 18/16 - Chemical coating by decomposition of either liquid compounds or solutions of the coating forming compounds, without leaving reaction products of surface material in the coatingContact plating by reduction or substitution, i.e. electroless plating
C25D 5/02 - Electroplating of selected surface areas
G03F 1/20 - Masks or mask blanks for imaging by charged particle beam [CPB] radiation, e.g. by electron beamPreparation thereof
93.
METHOD OF MATURING/DIFFERENTIATING NEURONS AND/OR MODULATING THE VAGUS NERVE
in vivoin vivoin vivo neuron maturation/differentiation and/or vagus nerve modulation by administering a therapeutic amount of a composition comprising IGF-1, for example in a complex with an IGF-1 binding protein, such as IBGBP-3.
A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
A61K 38/30 - Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
A61P 25/00 - Drugs for disorders of the nervous system
The present disclosure relates to methods for assessing the effects of a mutation of interest in a cell. Herein are also disclosed systems for assessing the effects of a mutation of interest in a cell. The disclosure also provides host cells and host cell populations comprising the system.
The present invention relates to virally expressed peptides which bind to PDZ domains and thereby block PDZ domain mediated protein-protein interactions and expression vectors encoding these peptides. The virally expressed peptides comprise an oligomerization domain, capable of forming higher order constructs, such as trimers or tetramers, and a peptide ligand capable of binding to a PDZ domain. The invention furthermore relates to therapeutic use of said peptides and expression vectors encoding these peptides.
The present disclosure relates to a lipid conjugated bivalent peptide ligand which bind to Protein Interacting with C Kinase-1 (PICK1) and thereby inhibit PICK1. The PICK1 inhibitors of the present disclosure comprise a peptide portion comprising two peptide ligands of PICK1, and a non-peptide portion comprising a linker, linking the two peptide ligands, and a lipid. The disclosure furthermore relates to therapeutic and diagnostic use of said PICK1 inhibitor for treatment of diseases or disorders associated with maladaptive plasticity.
A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
A61K 47/60 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
A61P 25/00 - Drugs for disorders of the nervous system
A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
97.
BIODEGRADABLE COMPOSITE MATERIAL OF PURE AMYLOSE AND CELLULOSE NANOFIBRES OR CELLULOSE NANOCRYSTALS
Disclosed herein are composite materials comprising amylose, cellulose nanofibres or cellulose nanocrystals, and a plasticiser. The amylose is of high purity, specifically containing little or no amylopectin. The cellulose nanofibres or cellulose nanocrystals act to reinforce the disclosed composite materials. Also disclosed are methods of producing such composite materials, and their use.
A chimeric non-human mammal disease model, wherein (1) at least 30% of all the glial cells in the corpus callosum of the chimeric non-human mammal are human glial cells, and/or (2) at least 5% of all of the glial cells in the white matter of the brain and/or brain stem of the chimeric non-human mammal are human glial cells, and wherein the human glial cells comprise a combination of a first group of human glial cells tagged with a first label and a second group of human glial cells tagged with a second label that is distinguishable from the first label.
The present disclosure regards a method for providing labeled single isomeric chemical entity targeting vectors suitable for providing targeting vectors. The method applies specific combinations between a diene and a dienophile with complementary inverse electron demand Diels-Alder cycloaddition reactivity, which upon ligation, followed by oxidation, will form compounds of a single isomeric form. The labeled single isomeric chemical entity targeting vectors are for use in therapy, radiotherapy, theranostics, diagnostics, and imaging. The method applies click chemistry wherein one chemical entity which is conjugated to a label is clicked together with a second chemical entity with complementary inverse electron demand Diels-Alder cycloaddition reactivity which is conjugated to a targeting vector followed by a rapid oxidation, to form a single isomeric compound.
C07B 59/00 - Introduction of isotopes of elements into organic compounds
C07D 209/94 - [b, c]- or [b, d]-condensed containing carbocyclic rings other than six-membered
C07D 241/42 - Benzopyrazines with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
C07D 257/10 - Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms condensed with carbocyclic rings or ring systems
C07D 401/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 209/52 - Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring condensed with a ring other than six-membered
100.
METHOD FOR PROVIDING A LABELED SINGLE ISOMERIC CHEMICAL ENTITY TARGETING VECTOR BASED ON THE USE OF AN ISOMER-FREE DIENOPHILE
The present disclosure regards a method for providing labeled single isomeric chemical entity targeting vectors suitable for providing targeting vectors. The method applies specific combinations between a diene and a dienophile with complementary inverse electron demand Diels-Alder cycloaddition reactivity, which upon ligation, followed by oxidation, will form compounds of a single isomeric form. The labeled single isomeric chemical entity targeting vectors are for use in therapy, radiotherapy, theranostics, diagnostics, and imaging. The method applies click chemistry wherein one chemical entity which is conjugated to a label is clicked together with a second chemical entity with complementary inverse electron demand Diels-Alder cycloaddition reactivity which is conjugated to a targeting vector followed by a rapid oxidation, to form a single isomeric compound.
C07B 59/00 - Introduction of isotopes of elements into organic compounds
C07D 209/52 - Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring condensed with a ring other than six-membered
C07D 209/94 - [b, c]- or [b, d]-condensed containing carbocyclic rings other than six-membered
C07D 241/42 - Benzopyrazines with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
C07D 257/10 - Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms condensed with carbocyclic rings or ring systems
C07D 401/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
